RxDoctor Payments Data

Rebecca Merli

Psychiatric/Mental Health · Rock Hill, SCNPI 1992399182

Payments from drug & device makers

$1,002in general payments, 2019–2025

Across 65 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$470
  • Takeda Pharmaceuticals U.S.A., Inc.$114
  • Otsuka America Pharmaceutical, Inc.$83
  • Neurocrine Biosciences, Inc.$73
  • Supernus Pharmaceuticals, Inc.$57
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • plus $158 from 5 others

What the payments were for

  • Food & beverage$97497%
  • Education$273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,002 in reported general payments places this provider in the 55th percentile of 354 psychiatric/mental health providers in South Carolina.

See all psychiatric/mental health providers in South Carolina

Medicare billing

Part B allowed, 2024
$5,730
Medicare patients
12
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole36$57,226
VraylarCariprazine Hcl19$31,732
Lisdexamfetamine Dimesylate13$2,831
Bupropion XlBupropion Hcl36$1,017
Buspirone Hcl40$818
Duloxetine Hcl38$812
Aripiprazole24$770
Mirtazapine28$764
Clozapine19$579
Lamotrigine22$570
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine15$558
Hydroxyzine Hcl16$345
Gabapentin13$344
Trazodone Hcl44$283
Divalproex Sodium ErDivalproex Sodium17$272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$83$57,22636 claims
AbbVieVraylar$470$31,73219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 354 psychiatric/mental health providers in South Carolina.

Other psychiatric/mental health in Rock Hill

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →